PARIS, Nov. 28, 2025 /PRNewswire/ — Sopra Steria, a major player in the European tech sector, has been ranked among the leaders in NelsonHall’s latest 2025 NEAT assessment for “GenAI-Enabled Operational Transformation”, particularly in the “Overall” category.
This recognition underlines the Group’s ability to industrialise GenAI to support the operational transformation of its clients, delivering fast, measurable benefits while meeting the requirements of major public- and private-sector organisations.
In this edition of the NEAT, Sopra Steria is recognised as a Leader in several key categories:
A robust AI strategy focused on operational impact
These results highlight the strategic direction taken by Sopra Steria to make AI a cornerstone of its offering, its operating model, and the value it delivers to its clients. Since 2023, the Group has accelerated its momentum around GenAI through:
These efforts directly translate into the Group’s ability to bring robust, secure GenAI solutions into production, rapidly generating ROI for its European clients.
Yves Nicolas, Director of the Group AI Programme at Sopra Steria, said: “NelsonHall’s recognition confirms that our AI strategy has reached maturity. We have deliberately chosen an impact-driven approach: understanding the real needs of our clients, developing trustworthy GenAI solutions, and, above all, industrialising them quickly to generate operational value where it is most needed. Being ranked as leaders in so many categories reflects the commitment of our teams and our ability to harness AI to deliver concrete, measurable and lasting transformation.”
Contact
Aurélien Flaugnatti
aurelien.flaugnatti@soprasteria.com
Logo – https://mma.prnewswire.com/media/1861938/Sopra_Steria_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sopra-steria-recognised-as-leader-by-nelsonhall-for-its-ability-to-deploy-genai-in-support-of-organisations-operational-transformation-302627749.html
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from…
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025…
February 04, 2026 09:35 ET | Source: Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Feb. 04,…
Patton®... Let's Connect! The liaison creates a powerful combination of manufacturing capabilities that significantly expands…
February 04, 2026 05:00 ET | Source: ChipMOS TECHNOLOGIES INC. HSINCHU, Taiwan, Feb. 04, 2026…
Industry-Leading Signal Processing and Algorithms Deliver Precise and Low Touch-Display Interference Across a Wide Range…